ELI LILLY & Co vs Merck & Co., Inc., two Drug Manufacturers stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Where LLY and MRK diverge most: on revenue growth, LLY reads +47.4% and MRK reads +2.9%; on p/b, LLY reads 34.68 and MRK reads 7.01. The rest of the comparable metrics sit closer together. On valuation, today's LLY price has a different growth bar priced in than MRK (+22.8% implied for LLY vs +11.4% for MRK); the higher figure is the steeper assumption to clear, not a better or worse stock. The bull and bear cases for each are in their full reports below.
| Metric | LLY | MRK |
|---|---|---|
| Price | $1148.86 | $130.21 |
| Market cap | $1.08T | $321.9B |
| Sector | Drug Manufacturers | Drug Manufacturers |
| Stage | Mature | Mature |
| Implied growth (priced in) | +22.8% | +11.4% |
| P/E | 40.8 | 36.7 |
| P/B | 34.68 | 7.01 |
| P/S | 14.97 | 4.89 |
| EV/EBITDA | 2200.4 | 629.4 |
| Revenue growth | +47.4% | +2.9% |
| Net margin | 35.0% | 13.6% |
| Return on equity | 81.0% | 19.4% |
| Return on assets | 21.7% | 6.9% |
| FCF yield | 1.9% | 4.4% |
| Dividend yield | 0.5% | 2.5% |
| Debt / equity | 1.39 | 1.07 |
| Current ratio | 1.50 | 1.30 |
| Altman Z (solvency) | 7.16 | 7.31 |
| Piotroski F (quality) | 6 / 9 | 6 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.